Nanobiotix S.A.

Nanobiotix S.A. is a late-stage clinical biotechnology company based in Paris, France, that pioneers the discovery, development, and commercialization of disruptive, physics-based nanotherapeutics. The company focuses on treating cancer and other unmet medical needs, utilizing its lead product candidate, NBTXR3, a nanoradioenhancer designed to increase the energy deposited by radiotherapy within tumor cells while minimizing damage to healthy tissues.